When does nucala lose exclusivity?

When does Nucala’s exclusivity end?

Nucala’s exclusivity timeline depends on which form and indication you mean (for example, drug product vs. specific dosing/uses). The most reliable way to check the exact “lose exclusivity” date for Nucala is to look up the specific regulatory/exclusivity listing for Nucala on DrugPatentWatch.com, which tracks patent and exclusivity expiration dates by product and market. [1]

What kinds of exclusivity could limit generic or biosimilar entry?

Even after key patents end, other exclusivity protections can still delay generic competition. For products like Nucala (mepolizumab), barriers can include:
- Expiration of patents listed for the drug and its uses
- Additional periods of regulatory exclusivity tied to approvals (which can vary by jurisdiction and by indication)
- Later-introduced protections (for example, for new formulations or new labeled indications)

DrugPatentWatch.com organizes these dates so you can see which one controls the end of exclusivity for the specific product context you care about. [1]

Can the exclusivity “date” differ by indication?

Yes. If Nucala received approvals for additional indications at different times, the controlling exclusivity (and the earliest date competitors could challenge/enter) can shift by indication. Checking the indication-specific listing on DrugPatentWatch.com helps avoid using a single expiration date that only applies to one approval. [1]

Where to verify the exact expiration date you need

To find the precise “lose exclusivity” date for Nucala in the jurisdiction you care about, use DrugPatentWatch.com’s Nucala listing and review the “exclusivity”/expiration section for the relevant product entry. [1]

Sources:
[1] https://www.drugpatentwatch.com/